Macro Insights - The US March CPI data was weaker than expected, with core CPI month-on-month dropping from 0.23% in February to 0.06%, and year-on-year at 2.8%, below the expected 3.0% [2] - The overall CPI month-on-month fell from 0.22% in February to -0.05%, with year-on-year CPI decreasing to 2.4%, both below expectations [2] - Despite the cooling inflation in March, market reactions were muted due to ongoing concerns about tariffs and their impacts, with little change in Fed rate cut expectations [2] Tariff Policy Analysis - On April 9, Trump announced a 90-day suspension of the reciprocal tariff plan, while imposing a 10% tariff on countries outside China, Mexico, and Canada, and increasing the reciprocal tariff on China to 145% [3] - Tariffs are expected to remain a frequently adjusted tool in Trump's negotiations, with potential for further increases against countries perceived as unfavorable [3] - The market may gradually become desensitized to tariff policy changes, with uncertainty becoming a new norm [3] Energy Price Impact - In March, China's CPI was -0.1% year-on-year, lower than the expected 0%, while PPI was -2.5%, also below expectations [4] - The decline in energy prices has contributed to the downward pressure on PPI, indicating a broader economic impact [4] Fixed Income Market Trends - The 10-year US Treasury yield rose sharply from 4.0% to around 4.5%, despite weakening economic fundamentals [5] - The bond market's significant adjustment occurred without drastic changes in macroeconomic data, raising investor concerns [6] Energy Sector Developments - The National Development and Reform Commission released a plan for upgrading coal power plants to enhance flexibility, indicating a market potential of 100-200 billion yuan annually [9] - Companies like Dongfang Electric are recommended due to their involvement in this transition [9] Aviation and Low-altitude Economy - The low-altitude economy is seen as a key area for investment, with potential market space reaching trillions, driven by regulatory changes and advancements in eVTOL technology [10] Company-Specific Insights - Chongqing Bank is covered for the first time with a buy/hold rating, targeting a PB of 0.70/0.47, benefiting from the Chengdu-Chongqing economic circle [12] - Anta Sports reported strong Q1 performance with retail growth across brands, maintaining a buy rating due to competitive advantages [13] - Yutong Heavy Industries showed a 77% increase in new energy vehicle sales, with a robust cash flow supporting its growth outlook [13] - Pinggao Electric is expected to see significant profit growth due to high voltage business expansion, with a buy rating maintained [17] - Wanfu Biology's international business led to a 10.9% revenue increase, with a buy rating supported by stable cash flow and margin improvements [29]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 27.07 RMB [7][8]. Core Insights - The company achieved revenue and net profit of 306.5 million RMB and 56.2 million RMB in 2024, representing year-over-year growth of 10.9% and 15.2%, respectively, although these figures fell short of market expectations [1]. - The gross margin for 2024 was 64.2%, an increase of 1.5 percentage points year-over-year, attributed to an optimized product revenue structure [1]. - The operating cash flow for 2024 was 362 million RMB, reflecting a 10.1% year-over-year increase, indicating a positive cash flow trend [1]. Revenue Growth Projections - The international department is expected to see a revenue increase of approximately 30% in 2024, driven by the expansion of immunofluorescence and single-use luminescence businesses [2]. - Domestic business is projected to grow by about 10% in 2024, supported by deeper market penetration in emergency departments and strategic engagement with higher-tier hospitals [2]. - The U.S. subsidiary is anticipated to experience a slight revenue decline in 2024 due to intensified competition in the North American toxicology testing market, but is expected to recover in 2025 with new product contributions [2]. Business Segment Performance - The infectious disease testing segment is projected to generate 1.042 billion RMB in revenue for 2024, with a year-over-year growth of 9.5%, driven by increasing demand for routine testing [3]. - The chronic disease testing segment is expected to achieve 1.369 billion RMB in revenue for 2024, reflecting a robust year-over-year growth of 22.4%, bolstered by steady promotion of immunofluorescence products [3]. - The toxicology and prenatal testing segments are forecasted to generate revenues of 286 million RMB and 294 million RMB, respectively, with the latter expected to grow by 10% year-over-year [3]. Profitability Forecast and Valuation - The report adjusts the company's revenue growth and sales expense rate forecasts, projecting net profits of 652 million RMB, 752 million RMB, and 867 million RMB for 2025-2027, with significant downward adjustments of 23.3% and 30.5% for 2025 and 2026, respectively [4]. - The company is positioned as a leader in the domestic POCT industry, with a diverse product range and ongoing commercialization efforts, warranting a 20x PE for 2025, leading to a target price of 27.07 RMB [4].

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 万孚生物(300482) | 上次评级 | 买入 | | --- | --- | | 投资评级 | 买入 | [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 夯实产品竞争力，业务实现高质量增长 盈利能力持续增强，多元化布局助力高 质量增长 新冠基数已消化，国际市场渐入收获期 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 境外业务快速发展，盈利能力稳中有升 [Table_ReportDate] 2025 年 04 月 10 日 [Table_S 事件：ummar 公司发布y] 2024 年年报，2024 年实现 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company achieved a revenue of 3.065 billion yuan in 2024, representing a year-on-year growth of 10.85%, with a net profit of 562 million yuan, up 15.18% year-on-year [1] - The overseas business is rapidly developing, with a 43% increase in foreign revenue driven by localized operations in developing countries and FDA EUA authorization for respiratory products in North America [2] - The company's diversified business lines show strong growth resilience, with significant contributions from chronic disease management and infectious disease testing [2] - Profitability is steadily improving due to optimized revenue structure and cost control, with a gross margin of 64.15% in 2024, up 1.54 percentage points year-on-year [2] - The company is expected to achieve revenues of 3.476 billion, 3.980 billion, and 4.554 billion yuan from 2025 to 2027, with corresponding net profits of 642 million, 746 million, and 877 million yuan, reflecting growth rates of 14.3%, 16.3%, and 17.5% respectively [2] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 3.065 billion yuan, a 10.85% increase from the previous year, and a net profit of 562 million yuan, marking a 15.18% increase [3] - The gross margin for 2024 was 64.15%, an increase of 1.54 percentage points year-on-year, while the overall net profit margin reached 18.44%, up 0.81 percentage points [2][3] Revenue Breakdown - Domestic revenue was 1.962 billion yuan, down 1.65% year-on-year, while overseas revenue reached 1.103 billion yuan, up 43.23% year-on-year [2] - The chronic disease management testing business generated 1.369 billion yuan, a 22.38% increase, while the infectious disease testing business brought in 1.042 billion yuan, up 9.50% [2] Future Projections - Revenue projections for 2025, 2026, and 2027 are 3.476 billion, 3.980 billion, and 4.554 billion yuan, with year-on-year growth rates of 13.4%, 14.5%, and 14.4% respectively [2][3] - Expected net profits for the same years are 642 million, 746 million, and 877 million yuan, with growth rates of 14.3%, 16.3%, and 17.5% [2][3]

外资态度来看，本期较上一季度持股减少的外资基金共计2个，包括香港中央结算有限公司、阿布达比 投资局，持股减少占比达0.21%。 2025年4月10日，万孚生物(300482.SZ)发布2024年年度报告。截至2025年4月09日，共有144个机构投资 者披露持有万孚生物A股股份，合计持股量达1.02亿股，占万孚生物总股本的21.27%。其中，前十大机 构投资者包括广州汇垠天粤股权投资基金管理有限公司、中国银行股份有限公司-华宝中证医疗交易型 开放式指数证券投资基金、广州生物医药与健康产业投资有限公司、广东恒阔投资管理有限公司、阿布 达比投资局、红杉锦程(厦门)股权投资合伙企业(有限合伙)、香港中央结算有限公司、南方中证 1000ETF、华夏中证1000ETF、工银前沿医疗股票A，前十大机构投资者合计持股比例达18.68%。相较 于上一季度，前十大机构持股比例合计下跌了1.11个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计1个，即华宝中证医疗ETF，持股增加占比小幅 上涨。本期较上一季度持股减少的公募基金共计4个，包括工银前沿医疗股票A、南方中证1000ETF、中 证1000ETF增强、东海社会安 ...

证券代码：300482 证券简称：万孚生物 公告编号：2025-006 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 立信会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所由变更为立信会计师事务所（特殊普通合 伙）。 非标准审计意见提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以公司未来实施2024年度利润分配方案时股权登记日的 总股本为基数，向全体股东每10股派发现金红利4元（含税），送红股0股（含税），以资本公积金向全 体股东每10股转增0股。 董事会决议通过的本报告期优先股利润分配预案 □适用 □不适用 二、公司基本情况 1、公司简介 ■ 公司是否需追溯调整或重述以前年度会计数据 □是 √否 （2） 分季度主要会计数据 单位：元 ■ 上 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-015 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于调整 2024 年限制性股票激励计划的回购价格及回购注销部分限 制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 特别提示： 广州万孚生物技术股份有限公司（以下简称"公司"或"万孚生物"）于 2025 年 4 月 9 日召开第五届董事第九次会议和第五届监事会第七次会议，审议通过《关 于调整 2024 年限制性股票激励计划的回购价格及回购注销部分限制性股票的议 案》。鉴于公司 2024 年限制性股票激励计划部分激励对象已离职不满足激励对象 资格，本激励计划首次授予部分第一个解除限售期公司层面业绩考核未达标，公 司决定回购注销 2024 年限制性股票激励计划部分限制性股票。具体情况如下： 一、本次激励计划已履行的相关审批程序 1、2024 年 7 月 3 日，公司召开第五届董事会第二次会议，会议审议通过了 《关于公司<2024 年限制性 ...

内部控制审计报告 信会师报字[2025]第 ZC10234 号 广州万孚生物技术股份有限公司全体股东： 按照《 企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了广州万孚生物技术股份有限公司《 以下简称贵公 司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 四、 财务报告内部控制审计意见 我们认为，贵公司于 2024 年 12 月 31 日按照 企业内部控制基 本规范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 广州万孚生物技术股份有限公司 信会师报字[2025]第 ZC10234 号 内控审计报告 第 1 页 此页无正文） 特殊普通合伙） 立信会计师事务所 中国注册会计师：梁肖林 按照《 企业内部控制基本规范》、 企业内部控制应用指引》、 企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 ...

华泰联合证券有限责任公司 关于广州万孚生物技术股份有限公司 2024 年度跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：万孚生物 | | --- | --- | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | | 保荐代表人姓名：沈钟杰 | 联系电话：010-56839300 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | | | | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | ...